Checkmate 142 Nivolumab & Ipilimumab 55Response Rate in MSI High - 101967

Spotlight
Video

Checkmate 142 Nivolumab & Ipilimumab 55Response Rate in MSI High

Loading........
Description: Cathy Eng, MD, FACP GASTROINTESTINAL MEDICAL ONCOLOGY - MD Anderson discusses the trial Checkmate 142 Nivolumab & Ipilimumab and how it has shown a 55% Response Rate in MSI High patients. Recorded at ASCO GI 2018.
Shared By : Gastrointestinal-Cancer-Meeting
Posted on : 01/25/18
Added : 3 months ago



Recommended

Nothing found.